Combined Antiangiogenic Therapy is Superior to Single Inhibitors in a Model of Renal Cell Carcinoma

Journal of Urology

Volumn 179, Issue 1, 2008, Pages 326-332

  Bartsch Jr , Georg ^a   Eggert, Katharina ^b   Soker, Shay ^c   Bokemeyer, Carsten ^b   Hautmann, Richard ^a   Schuch, Gunter ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

carcinoma; endostatins; kidney; neuropilins; renal cell; thrombospondins

Indexed keywords

ENDOSTATIN; NEUROPILIN 1; THROMBOSPONDIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AORTA; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER SIZE; CELL FUNCTION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG RELEASE; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; MICROENCAPSULATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWINE; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDOSTATINS; KIDNEY NEOPLASMS; MICE; NEUROPILIN-1; THROMBOSPONDINS; TUMOR CELLS, CULTURED;

EID: 36749058532     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.08.086     Document Type: Article

References (20)

1. Drucker B.J. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 31 (2005) 536
2. McDermott D.F., Regan M.M., Clark J.I., Flaherty L.E., Weiss G.R., Logan T.F., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133
3. George D.J., and Kaelin Jr. W.G. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 349 (2003) 419
4. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427
5. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115
6. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125
7. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271
8. Wickstrom S.A., Alitalo K., and Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 62 (2002) 5580
9. Kim Y.M., Hwang S., Kim Y.M., Pyun B.J., Kim T.Y., Lee S.T., et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277 (2002) 27872
10. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., and Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6 (2000) 41
11. Mamluk R., Gechtman Z., Kutcher M.E., Gasiunas N., Gallagher J., and Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 277 (2002) 24818
12. Schuch G., Oliveira-Ferrer L., Loges S., Laack E., Bokemeyer C., Hossfeld D.K., et al. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia 19 (2005) 1312
13. Schuch G., Machlouf M., Bartsch Jr., Nomi M., Richard H., Atala A., et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood 100 (2002) 4622
14. Merchan J.R., Liu G., Fitch T., Picus J., Qin R., Pitot H.C., et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol, suppl 25 (2007) 5034
15. Modlich U., Kustikova O.S., Schmidt M., Rudolph C., Meyer J., Li Z., et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105 (2005) 4235
16. Szary J., and Szala S. Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth. Int J Cancer 91 (2001) 835
17. Weiss J.M., Shivakumar R., Feller S., Li L.H., Hanson A., Fogler W., et al. Rapid, in vivo, evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells. Cancer Gene Ther 11 (2004) 346
18. Miyata Y., Koga S., Takehara K., Kanetake H., and Kanda S. Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis. Clin Cancer Res 9 (2003) 1734
19. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998) 735
20. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277